30 results about "Nkg2d receptor" patented technology

The invention belongs to the technical field of biology, and relates to a method for differentiating human induced pluripotent stem cells into natural killer cells. The method comprises the following steps of 1, differentiating the human induced pluripotent stem cells to form endothelial progenitor cells with expression of KDR+CD73+; 2, performing endothelial-blood conversion on the endothelial progenitor cells with the expression of KDR+CD73+ to form NK progenitor cells with the expression of CD34-CD45+; and 3, further differentiating the NK progenitor cells into NK cells with expression of CD56+CD3-. The NK cells produced by the scheme provided by the invention highly express NKG2D receptors, and have stronger cytokine secretion ability and tumor killing ability.

A combination therapy of a cancer with a multi-specific binding protein that bind a tumor associated antigen, the NKG2D receptor, and CD16, in combination with a second anti-cancer agent are described. Also described are pharmaceutical compositions of the multi-specific binding protein, and therapeutic methods useful for the treatment of cancer in combination with a second anti-cancer agent.

Multi-specific binding proteins that bind PSMA, the NKG2D receptor, and CD 16 are described, as well as pharmaceutical compositions and therapeutic methods useful for the treatment of cancer.

Multi-specific binding proteins that bind the NKG2D receptor, CD16, and a tumor- associated antigen are described, as well as pharmaceutical compositions and therapeutic methods useful for the treatment of cancer.

Multi-specific binding proteins that bind NKG2D receptor, CD 16, and a tumor- associated antigen (e.g, B7-H3, L1CAM, FLT1, KDR, TNC, TNN, CSPG4, BST1, SELF, CD200, INSR (HHF5), ITGA6, MELTF, PECAM1, or SLC1A5) are described, as well as pharmaceutical compositions and therapeutic methods useful for the treatment of cancer.

The present invention relates to multispecific binding proteins targeting CAIX, ANO1, mesothelin, TROP2, or a claudin-18.2. In particular. Specifically, the present invention describes multispecific binding proteins that bind to the NKG2D receptor, CD16 and a tumor-associated antigen selected from the group consisting of carbonic anhydrase 9 (CAIX), calcitonin 1 (ANO1), mesothelin, TROP2, CEA and claudin-18.2, as well as pharmaceutical compositions and methods of treatment useful in the treatment of cancer.

Multi-specific binding proteins that bind a tumor associated antigen, the NKG2D receptor, and CD 16 are described, as well as pharmaceutical compositions and therapeutic methods useful for the treatment of cancer.

Antibody heavy chain variable domains that can be paired with antibody light chain variable domains to form an antigen-binding site targeting the NKG2D receptor on natural killer cells are described.Proteins comprising an NKG2D antigen-binding site, pharmaceutical compositions and therapeutic methods thereof, including for the treatment of cancer, are also described.

The present application relates to the field of immunotherapy, more particularly to the manufacture of cells for adoptive cell therapy. Provided herein are methods to prevent and/or reduce fratricideduring manufacturing of such cells, particularly of cells expressing a chimeric NKG2D receptor. Also provided are cells and compositions comprising cells in which fratricide is prevented and/or reduced.

Multi-specific binding proteins that bind GD2, the NKG2D receptor, and CD 16 are described, as well as pharmaceutical compositions and therapeutic methods useful for the treatment of cancer.

The present invention relates to [alpha] [beta] T cells genetically modified to express a recombinant chimeric antigen receptor (CAR) wherein the recombinant CAR comprises (a) an extracellular domain comprising an antigen binding region, (b) a transmembrane domain, (c) a co-stimulatory signaling domain, and (d) an intracellular signaling domain wherein the extracellular domain comprises an extracellular domain of the NKG2D receptor, and wherein the intracellular signaling domain comprises an immune receptor tyrosine-based activation motif (ITAM); a recombinant CAR for modifying an alpha beta T cell; a pharmaceutical composition comprising genetically modified [alpha] [beta] T cells; methods of treating cancer or tumors using the genetically modified [alpha] [beta] T cells; and methods of making genetically modified alpha beta T cells. In one embodiment, a genetically modified [alpha] [beta] T cell comprises a CAR comprising an extracellular domain of the NKG2D receptor, an IgG4 hinge region, a CD28 transmembrane domain, a 4-1BB co-stimulatory signaling domain, and a DAP 12 domain comprising a single ITAM.

Provided are a fusion protein used in a CRISPR/Cas system, and a complex including the same and use thereof. Since the gene editing complex including the fusion protein of the present disclosure includes an NKG2D ligand capable of binding to NKG2D expressed on the membrane of natural killer cells, it may be specifically delivered to NKG2D receptor-expressing cells or natural killer cells. Since it may be effectively delivered into the cells through endocytosis of NKG2D without a carrier, a target gene or a target DNA of NKG2D receptor-expressing cells or natural killer cells may be manipulated using the complex.

Multi-specific binding proteins that bind NKG2D receptor, CD16, and P-cadherin, as well as pharmaceutical compositions and therapeutic methods useful for the treatment of cancer.

The invention relates to an EpCAM-CD16-NKG2D trispecific antibody and an application thereof. The EpCAM-CD16-NKG2D trispecific antibody comprises an EpCAM binding domain, a CD16 binding domain and an NKG2D ligand binding domain. According to the EpCAM-CD16-NKG2D trispecific antibody constructed by the invention, an NKG2D receptor is added on the basis of an EpCAM * CD16 bispecific antibody, and the EpCAM-CD16-NKG2D trispecific antibody can be used for immune cells not only to target tumor cells expressing EpCAM in an epithelial state, but also to target tumor cells expressing NKG2D ligands in a mesenchymal state, or target tumor cells expressing both the EpCAM and the NKG2D ligands in a mixed state, so that stronger ability of immune cells to resist migration tumors can be mediated.

Multi-specific binding proteins that bind NKG2D receptor, CD16, and 5T4, a tumor-associated antigen selected from 5T4, GPNMB, FR-alpha, PAPP-A, and GPC3 are described, as well as pharmaceutical compositions and therapeutic methods useful for the treatment of cancer.

A polypeptide is disclosed that binds tumor-associated antigens (TAA) on the surface of cancer cells and a NKG2D receptor. The NKG2D receptor is expressed on the surfaces of killer cells such as natural killer cells, T cells, natural killer T cells, and gamma delta T cells. In some cases, the TAA is CS-1 or EGFRvIII. Also disclosed are polynucleotides encoding the disclosed polypeptides, vectors comprising the disclosed polynucleotides, and host cells comprising the disclosed vectors. Also disclosed are bivalent antibodies comprising the disclosed polypeptides. Also disclosed are pharmaceutical compositions comprising the disclosed antibodies. Also disclosed are methods of treating cancer in a subject using the disclosed bi-specific antibodies.

Multi-specific binding proteins that bind NKG2D receptor, CD 16, and a tumor-associated antigen FLT3 are described, as well as pharmaceutical compositions and therapeutic methods useful for the treatment of cancer.

The invention discloses a soluble NK-CAR fusion protein, a preparation method and an application of the soluble NK-CAR fusion protein in a drug for mediating immune cells to target tumor cells. The fusion protein is composed of an MICA extracellular region, a single-chain antibody and a human IgG Fc terminal from an amino terminal to a carboxyl terminal. A nucleotide sequence for coding the protein is inserted into an eukaryotic expression vector and transfected to an HEK293 suspension cell for protein expression, then purification is carried out through an SPA column, the protein is in a dimer state in an aqueous solution, a CD20 single-chain antibody of the protein can be combined with a CD20 antigen on a target cell, an MICA terminal is combined with an NKG2D receptor on an NK cell to activate the NK cell to play a role in specifically killing the target cell, and the target cell is killed. The invention lays a foundation for development and application of biological medicines for specifically killing tumor target cells by mediating NK cells and CD8 + T cells.

Multi-specific binding proteins that bind NKG2D receptor, CD16, and fibroblast activation protein (FAP) are described, as well as pharmaceutical compositions and therapeutic methods of the multi- specific binding proteins useful for the treatment of cancer, autoimmune disease, or fibrosis.

Multi-specific binding proteins that bind CD123, the NKG2D receptor, and CD16 are described, as well as pharmaceutical compositions and therapeutic methods useful for the treatment of cancer.

Multi-specific binding proteins that bind NKG2D receptor, CD 16, and a tumor- associated antigen ROR1 or ROR2 are described, as well as pharmaceutical compositions therapeutic methods useful for the treatment of cancer.